<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepatol Commun</journal-id><journal-id journal-id-type="iso-abbrev">Hepatol Commun</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2471-254X</journal-id><journal-id journal-id-type="publisher-id">HEP4</journal-id><journal-title-group><journal-title>Hepatology Communications</journal-title></journal-title-group><issn pub-type="epub">2471-254X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29761171</article-id><article-id pub-id-type="pmc">5944587</article-id><article-id pub-id-type="doi">10.1002/hep4.1171</article-id><article-id pub-id-type="publisher-id">HEP41171</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Coding variants in <italic>PNPLA3</italic> and <italic>TM6SF2</italic> are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist</article-title><alt-title alt-title-type="left-running-head">Guzman et al.</alt-title></title-group><contrib-group><contrib id="hep41171-cr-0001" contrib-type="author"><name><surname>Guzman</surname><given-names>Cristina B.</given-names></name><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="hep41171-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="hep41171-cr-0002" contrib-type="author"><name><surname>Duvvuru</surname><given-names>Suman</given-names></name><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="hep41171-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="hep41171-cr-0003" contrib-type="author"><name><surname>Akkari</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="hep41171-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="hep41171-cr-0004" contrib-type="author"><name><surname>Bhatnagar</surname><given-names>Pallav</given-names></name><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="hep41171-cr-0005" contrib-type="author"><name><surname>Battioui</surname><given-names>Chakib</given-names></name><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="hep41171-cr-0006" contrib-type="author"><name><surname>Foster</surname><given-names>Wendra</given-names></name><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="hep41171-cr-0007" contrib-type="author"><name><surname>Zhang</surname><given-names>Xiaotian Michelle</given-names></name><xref ref-type="aff" rid="hep41171-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="hep41171-cr-0008" contrib-type="author"><name><surname>Shankar</surname><given-names>Sudha S.</given-names></name><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="hep41171-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="hep41171-cr-0009" contrib-type="author"><name><surname>Deeg</surname><given-names>Mark A.</given-names></name><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="hep41171-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="hep41171-cr-0010" contrib-type="author" corresp="yes"><name><surname>Chalasani</surname><given-names>Naga</given-names></name><address><email>nchalasa@iu.edu</email></address><xref ref-type="aff" rid="hep41171-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="hep41171-cr-0011" contrib-type="author"><name><surname>Hardy</surname><given-names>Thomas A.</given-names></name><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="hep41171-cr-0012" contrib-type="author"><name><surname>Kazda</surname><given-names>Christof M.</given-names></name><xref ref-type="aff" rid="hep41171-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="hep41171-cr-0013" contrib-type="author" corresp="yes"><name><surname>Pillai</surname><given-names>Sreekumar G.</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7385-4953</contrib-id><address><email>pillai_sreekumar_g@lilly.com</email></address><xref ref-type="aff" rid="hep41171-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="hep41171-aff-0001">
<label><sup>1</sup></label>
<institution>Eli Lilly and Company</institution>
<named-content content-type="city">Indianapolis</named-content>
<named-content content-type="country-part">IN</named-content>
</aff><aff id="hep41171-aff-0002">
<label><sup>2</sup></label>
<institution>Cabernet Pharmaceuticals</institution>
<named-content content-type="city">Durham</named-content>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="hep41171-aff-0003">
<label><sup>3</sup></label>
<institution>Eli Lilly and Company</institution>
<named-content content-type="city">Toronto</named-content>
<country country="CA">Canada</country>
</aff><aff id="hep41171-aff-0004">
<label><sup>4</sup></label>
<institution>Indiana University Department of Medicine</institution>
<named-content content-type="city">Indianapolis</named-content>
<named-content content-type="country-part">IN</named-content>
</aff><aff id="hep41171-aff-0005">
<label><sup>5</sup></label>
<institution>Eli Lilly and Company</institution>
<named-content content-type="city">Neuilly sur Seine</named-content>
<country country="FR">France</country>
</aff><aff id="hep41171-aff-0006"><label><sup>6</sup></label>Present address:
<institution>Amazon</institution>
<named-content content-type="city">Seattle</named-content>
<named-content content-type="country-part">WA</named-content>
</aff><aff id="hep41171-aff-0007"><label><sup>7</sup></label>Present address:
<institution>NGM Biopharmaceuticals</institution>
<named-content content-type="city">San Francisco</named-content>
<named-content content-type="country-part">CA</named-content>
</aff><aff id="hep41171-aff-0008"><label><sup>8</sup></label>Present address:
<institution>Regulus Pharmaceuticals</institution>
<named-content content-type="city">San Diego</named-content>
<named-content content-type="country-part">CA</named-content>
</aff><aff id="hep41171-aff-0009"><label><sup>9</sup></label>Present address:
<institution>Enanta Pharmaceuticals Inc</institution>
<named-content content-type="city">Watertown</named-content>
<named-content content-type="country-part">MA</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:</bold><break/>Sreekumar G. Pillai, Ph.D.<break/>Eli Lilly and Company<break/>Indianapolis, IN<break/>E&#x02010;mail: <email>pillai_sreekumar_g@lilly.com</email><break/>Tel: +1&#x02010;317&#x02010;433&#x02010;8631<break/>or<break/>Naga Chalasani, M.D.<break/>Indiana University Department of Medicine<break/>Indianapolis, IN<break/>E&#x02010;mail: <email>nchalasa@iu.edu</email><break/>Tel: +1&#x02010;317&#x02010;278&#x02010;0414<break/></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2018</year></pub-date><volume>2</volume><issue>5</issue><issue-id pub-id-type="doi">10.1002/hep4.v2.5</issue-id><fpage>561</fpage><lpage>570</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2017</year></date><date date-type="rev-recd"><day>05</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 by the American Association for the Study of Liver Diseases. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:HEP4-2-561.pdf"/><abstract><p>LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated alanine aminotransferases (ALTs) associated with LY2409021. Patients participated in a 6&#x02010;week placebo&#x02010;controlled trial (I1R&#x02010;MC&#x02010;GLDI [GLDI], n = 246) and a 52&#x02010;week placebo&#x02010; and active comparator&#x02010;controlled trial (I1R&#x02010;MC&#x02010;GLDJ [GLDJ], n = 158). GLDJ had endpoints at 6 months, including measures of hepatic fat fraction (HFF) by magnetic resonance imaging. The five genes tested were patatin&#x02010;like phospholipase domain containing 3 (<italic>PNPLA3</italic>) (rs738409 and rs738491), transmembrane 6 superfamily member 2 (<italic>TM6SF2</italic>) (rs58542926), peroxisome proliferative activated receptor gamma coactivator 1 alpha (<italic>PPARGC1A</italic>) (rs4361373, rs3774921, rs2970849), adenylate cyclase 3 (<italic>ADCY3</italic>) <italic>(</italic>rs713586), and insulin&#x02010;like growth factor 1 (<italic>IGF&#x02010;1</italic>) (rs1520220). In GLDI, <italic>PNPLA3</italic> I148M (<italic>P</italic> = 0.001) and <italic>TM6SF2</italic> E167K (<italic>P</italic> = 0.001) were significantly associated with an increase in ALT at 6 weeks for LY2409021 but not for placebo. In GLDJ, <italic>PNPLA3</italic> I148M showed the same effect (<italic>P</italic> = 0.007) on ALT at 6 months but the placebo or sitagliptin did not. In GLDJ, both PNPLA3 and TM6SF2 risk&#x02010;allele carriers showed increases in HFF that were numerically greater but not statistically significant. The carriers of <italic>PNPLA3</italic> and/or <italic>TM6SF2</italic> risk alleles showed significantly increased ALT (GLDI, +13.28 U/L in carriers versus +4.84 U/L in noncarriers, <italic>P</italic> = 4 &#x000d7; 10<sup>&#x02013;5</sup>; GLDJ, +14.6 U/L in carriers versus +1.7 in noncarriers, <italic>P</italic> = 0.0018) and HFF (GLDJ, +5.35% in carriers versus 2.38% in noncarriers, <italic>P</italic> = 0.048). Elevation of transaminase and HFF were also noted in the noncarriers but at a significantly lower degree. <italic>Conclusion:</italic> The carriers of <italic>PNPLA3</italic> and/or <italic>TM6SF2</italic> variant alleles are at risk for hepatic steatosis and elevated ALT levels caused by LY2409021, a glucagon receptor antagonist. More studies are needed to investigate if our observations are generalizable to hepatic steatosis caused by other medications. (<italic>Hepatology Communications</italic> 2018;2:561&#x02010;570)</p></abstract><funding-group><award-group><funding-source>Eli Lilly and Company
</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="10"/><word-count count="6297"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>hep41171</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.7.2 mode:remove_FC converted:10.05.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="hep41171-note-0001"><p>Potential conflict of interest: Dr. Guzman, Dr. Kazda, Ms. Foster, Dr. Pillai, Dr. Bhatnagar, Dr. Zhang, and Dr. Hardy are employed by and own stock in Eli Lilly; Dr. Deeg owns stock in Eli Lilly and Regulus and was an employee of Eli Lilly; Dr. Chalasani consults for Eli Lilly; Dr. Shankar was employed by Eli Lilly and owns stock in NGM Bio; Dr. Akkari has no conflict of interest with respect to this study.</p></fn><fn id="hep41171-note-0002"><p>Supported by Eli Lilly and Company in its entirety.</p></fn></fn-group></notes></front><body><def-list list-content="abbreviations" id="hep41171-lp-0001"><title>Abbreviations</title><def-item><term id="hep41171-li-0001">ADCY3</term><def id="hep41171-li-0002"><p>adenylate cyclase 3</p></def></def-item><def-item><term id="hep41171-li-0003">ALT</term><def id="hep41171-li-0004"><p>alanine aminotransferase</p></def></def-item><def-item><term id="hep41171-li-0005">AST</term><def id="hep41171-li-0006"><p>aspartate aminotransferase</p></def></def-item><def-item><term id="hep41171-li-0007">BP</term><def id="hep41171-li-0008"><p>blood pressure</p></def></def-item><def-item><term id="hep41171-li-0009">CFB</term><def id="hep41171-li-0010"><p>change from baseline</p></def></def-item><def-item><term id="hep41171-li-0011">GCGR</term><def id="hep41171-li-0012"><p>glucagon receptor</p></def></def-item><def-item><term id="hep41171-li-0013">GLDI</term><def id="hep41171-li-0014"><p>I1R&#x02010;MC&#x02010;GLDI</p></def></def-item><def-item><term id="hep41171-li-0015">GLDJ</term><def id="hep41171-li-0016"><p>I1R&#x02010;MC&#x02010;GLDJ</p></def></def-item><def-item><term id="hep41171-li-0017">HbA1c</term><def id="hep41171-li-0018"><p>hemoglobin A1c</p></def></def-item><def-item><term id="hep41171-li-0019">HFF</term><def id="hep41171-li-0020"><p>hepatic fat fraction</p></def></def-item><def-item><term id="hep41171-li-0021">HSC</term><def id="hep41171-li-0022"><p>hepatic stellate cell</p></def></def-item><def-item><term id="hep41171-li-0023">IGF&#x02010;1</term><def id="hep41171-li-0024"><p>insulin&#x02010;like growth factor 1</p></def></def-item><def-item><term id="hep41171-li-0025">MRI</term><def id="hep41171-li-0026"><p>magnetic resonance imaging</p></def></def-item><def-item><term id="hep41171-li-0027">NAFLD</term><def id="hep41171-li-0028"><p>nonalcoholic fatty liver disease</p></def></def-item><def-item><term id="hep41171-li-0029">NASH</term><def id="hep41171-li-0030"><p>nonalcoholic steatohepatitis</p></def></def-item><def-item><term id="hep41171-li-0031">PNPLA3</term><def id="hep41171-li-0032"><p>patatin&#x02010;like phospholipase domain containing 3</p></def></def-item><def-item><term id="hep41171-li-0033">PPARGC1A</term><def id="hep41171-li-0034"><p>peroxisome proliferative activated receptor gamma coactivator 1 alpha</p></def></def-item><def-item><term id="hep41171-li-0035">SNP</term><def id="hep41171-li-0036"><p>single nucleotide polymorphism</p></def></def-item><def-item><term id="hep41171-li-0037">T2D</term><def id="hep41171-li-0038"><p>type2 diabetes</p></def></def-item><def-item><term id="hep41171-li-0039">TM6SF2</term><def id="hep41171-li-0040"><p>transmembrane 6 superfamily member 2</p></def></def-item></def-list><p>Dysregulated glucagon secretion with resultant hepatic glucose overproduction<xref rid="hep41171-bib-0001" ref-type="ref">1</xref>, <xref rid="hep41171-bib-0002" ref-type="ref">2</xref>, <xref rid="hep41171-bib-0003" ref-type="ref">3</xref> is an important pathophysiologic feature that contributes to chronic hyperglycemia in type 2 diabetes (T2D), and glucagon receptor antagonism has been shown to diminish hepatic glucose output and improve both fasting and postprandial hyperglycemia.<xref rid="hep41171-bib-0004" ref-type="ref">4</xref>, <xref rid="hep41171-bib-0005" ref-type="ref">5</xref> There are currently several molecules in different stages of clinical development that target the inhibition of glucagon action, including small molecule antagonists, humanized antibodies, and antisense oligonucleotides. Although some of these molecules have demonstrated promising effects on lowering glucose, they have also shown elevation in serum aminotransferase levels in clinical trials.<xref rid="hep41171-bib-0006" ref-type="ref">6</xref>, <xref rid="hep41171-bib-0007" ref-type="ref">7</xref>, <xref rid="hep41171-bib-0008" ref-type="ref">8</xref>, <xref rid="hep41171-bib-0009" ref-type="ref">9</xref>, <xref rid="hep41171-bib-0010" ref-type="ref">10</xref>, <xref rid="hep41171-bib-0011" ref-type="ref">11</xref>, <xref rid="hep41171-bib-0012" ref-type="ref">12</xref>, <xref rid="hep41171-bib-0013" ref-type="ref">13</xref> LY2409021, administered orally once daily, is a novel agent with a long half&#x02010;life (approximately 60 hours) that competitively blocks the glucagon receptor. Recent results from an LY2409021 study have shown not only elevation of aminotransferases but also evidence of hepatic fat accumulation following treatment for 6 months in T2D.<xref rid="hep41171-bib-0014" ref-type="ref">14</xref>
</p><p>Epidemiologic, familial, and twin studies provide evidence for heritability of hepatic steatosis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and NASH cirrhosis.<xref rid="hep41171-bib-0015" ref-type="ref">15</xref>, <xref rid="hep41171-bib-0016" ref-type="ref">16</xref> Genome&#x02010;wide association studies have reported genetic variants associated with liver fat accumulation.<xref rid="hep41171-bib-0017" ref-type="ref">17</xref>, <xref rid="hep41171-bib-0018" ref-type="ref">18</xref>, <xref rid="hep41171-bib-0019" ref-type="ref">19</xref>, <xref rid="hep41171-bib-0020" ref-type="ref">20</xref> These studies have identified nonsynonymous coding variants in patatin&#x02010;like phospholipase domain containing 3 (<italic>PNPLA3</italic>) (I148M) and transmembrane 6 superfamily member 2 (<italic>TM6SF2</italic>) (E167K) that are significantly associated with steatosis.<xref rid="hep41171-bib-0018" ref-type="ref">18</xref>, <xref rid="hep41171-bib-0019" ref-type="ref">19</xref> These genetic variants have recently been extensively studied as risk factors for liver fat accumulation and progression to NASH.<xref rid="hep41171-bib-0021" ref-type="ref">21</xref>, <xref rid="hep41171-bib-0022" ref-type="ref">22</xref> Because patients carrying risk alleles of <italic>PNPLA3</italic> and <italic>TM6SF2</italic> are at risk for increased liver fat deposition in the general population, it is possible that patients who carry the risk alleles are at a higher risk for liver fat accumulation upon chronic treatment with LY2409021. We investigated the association between <italic>PNPLA3</italic> and <italic>TM6SF2</italic> variants and aminotransferase elevations and hepatic steatosis (as measured by hepatic fat fraction [HFF]) caused by LY2409021 among individuals with T2D who participated in two randomized controlled studies.</p><sec id="hep41171-sec-0002"><title>Materials and Methods</title><sec id="hep41171-sec-0003"><title>STUDY POPULATIONS</title><p>Patients with T2D enrolled in two phase 2 randomized clinical trials investigating LY2409021 were included in these analyses. The studies were conducted in accordance with regulatory standards of good clinical practice, the Declaration of Helsinki, and all applicable local regulations. Patients who provided written informed consent for genetic testing were included.</p><sec id="hep41171-sec-0004"><title>I1R&#x02010;MC&#x02010;GLDI</title><p>I1R&#x02010;MC&#x02010;GLDI (GLDI), an ambulatory blood pressure (BP) monitoring study (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02091362">https://clinicaltrials.gov/ct2/show/NCT02091362</ext-link>), was a 6&#x02010;week, phase 2, randomized, crossover study that evaluated the effects of once&#x02010;daily administration of LY2409021 20 mg versus placebo on systolic BP, diastolic BP, and mean arterial pressure using 24&#x02010;hour ambulatory BP monitoring. A 4&#x02010;week washout period was included between the two treatment periods to ensure complete washout of LY2409021 before starting the second period of treatment. More details of the study are reported elsewhere<xref rid="hep41171-bib-0009" ref-type="ref">9</xref> and in <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full">http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full</ext-link>.</p></sec><sec id="hep41171-sec-0005"><title>I1R&#x02010;MC&#x02010;GLDJ</title><p>I1R&#x02010;MC&#x02010;GLDJ (GLDJ), a hepatic safety study (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02111096">https://clinicaltrials.gov/ct2/show/NCT02111096</ext-link>), was a phase 2b, randomized, double&#x02010;blind, placebo&#x02010; and active comparator&#x02010;controlled study designed to evaluate changes in liver fat after 6 months of treatment (primary endpoint) and after a total treatment period of 12 months. Adult patients with T2D who were on an optimally effective and stable dose of metformin and a sulfonylurea were recruited into the study. More details of the study are reported elsewhere<xref rid="hep41171-bib-0014" ref-type="ref">14</xref> and in <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full">http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full</ext-link>. Patients were randomized in a 3:3:2 ratio and received double&#x02010;blinded LY2409021 (20 mg), placebo, or sitagliptin (100 mg), respectively, administered orally once daily.</p></sec></sec><sec id="hep41171-sec-0006"><title>OUTCOME MEASUREMENTS</title><p>Serum aminotransferases were measured using commercially validated methods and were available in both GLDI and GLDJ studies. Liver fat content was assessed as HFF measured by noncontrast magnetic resonance imaging (MRI) in the GLDJ study. Each baseline MRI was quality reviewed and approved by the core imaging laboratory before randomizing the patient. MRIs performed at baseline, 1, 3, 6, and 12 months from first treatment dose; at early discontinuation (if applicable); and at 4 months posttreatment were used to characterize the extent, time course, and reversibility of changes in HFF. More details about the MRI procedure are described in the original study manuscript.<xref rid="hep41171-bib-0014" ref-type="ref">14</xref> For this analysis, HFF was available at baseline, 1 month, 3 months, and at the time of the primary endpoint at 6 months.</p></sec><sec id="hep41171-sec-0007"><title>GENOTYPING</title><p>All samples were genotyped using the Axiom genotyping array from Affymetrix. A total of 418 samples (256 from GLDI; 162 from GLDJ) along with duplicates and haplotype map controls were used, and data for &#x0223c;765,000 single nucleotide polymorphisms (SNPs) were generated. Standard metrics of genome&#x02010;wide data quality control were used, and 404 samples (GLDI, 246; GLDJ, 158) and &#x0223c;680,000 SNPs passed quality control. Based on our <italic>a priori</italic> knowledge and understanding of disease mechanisms and genetic analysis results from prior phase 1 and phase 2 LY2409021 studies (unpublished data), eight SNPs from five candidate genes were tested for association with elevated aminotransferases and HFF. These were rs713586 for adenylate cyclase 3 (<italic>ADCY3</italic>), rs4361373, rs3774921, and rs2970849 for peroxisome proliferative activated receptor gamma coactivator 1 alpha (<italic>PPARGC1A</italic>), rs738409 and rs738491 for <italic>PNPLA3</italic>, rs1520220 for insulin&#x02010;like growth factor 1 (<italic>IGF&#x02010;1</italic>), and rs58542926 for <italic>TM6SF2</italic>. All the tested SNPs were in Hardy&#x02013;Weinberg equilibrium.</p></sec><sec id="hep41171-sec-0008"><title>STATISTICAL ANALYSIS</title><p>A linear model appropriate for the crossover design of the study was used for the association analyses in GLDI. Because GLDI used a crossover design, all patients received either placebo or LY2409021 at each treatment period. The model included change from baseline (CFB) at 6 weeks as the response variable and consisted of treatment sequence, period, treatment, genotype, genotype&#x02010;by&#x02010;treatment interaction, and the baseline measurement as covariates. In GLDJ, analysis of covariance models were used to assess the association between CFB for each endpoint and the SNPs. The model included CFB for each endpoint as the response variable with genotype as a categorical variable, and with treatment, genotype&#x02010;by&#x02010;treatment interaction, baseline hemoglobin A1c (HbA1c) stratum (&#x02264;8.0%, &#x0003e;8.0%), and baseline measurements of the respective endpoint as covariates. In both studies, the effect of genotype on the endpoint within each treatment arm was also assessed with similar models and covariate adjustments.</p><p>For the combined analyses of <italic>PNPLA3</italic> and <italic>TM6SF2</italic> SNPs, a risk&#x02010;allele carrier status was first defined by the status of carrying at least one risk&#x02010;allele copy of <italic>PNPLA3</italic> (M allele) or <italic>TM6SF2</italic> (K allele). Two models were run for the combined SNP analyses for each study. First, in GLDI and GLDJ, individual SNP analyses were used except that the carrier status was used as the predictor for the response variable instead of individual genotype effect (Model 1). Second, a regression model was run using additive allelic dosage calculated as the sum of risk alleles from <italic>PNPLA</italic>3 and <italic>TM6SF2</italic> SNPs (Model 2). For comparison, both <italic>P</italic> values from Model 1 and Model 2 are reported.</p><p>Bonferroni corrections for multiplicity were done for the primary hypothesis testing; a prespecified adjusted <italic>P</italic> value of 0.10 was considered significant. No multiplicity adjustments were applied in the joint analyses of <italic>PNPLA3</italic> and <italic>TM6SF2</italic> SNPs.</p></sec></sec><sec id="hep41171-sec-0009"><title>Results</title><sec id="hep41171-sec-0010"><title>BASELINE ANTHROPOMETRIC AND METABOLIC CHARACTERISTICS</title><p>A total of 246 patients from GLDI and 158 from GLDJ (LY2409021, n = 60; placebo, n = 60; sitagliptin, n = 38) were included in the pharmacogenetic analyses. Baseline characteristics of the patients included in these analyses are reported in Table <xref rid="hep41171-tbl-0001" ref-type="table-wrap">1</xref>. Mean age, body mass index, and baseline aminotransferase levels were comparable between studies. Additional baseline characteristics by genotype groups of <italic>PNPLA3</italic>&#x000a0;I148M and <italic>TM6SF2</italic>&#x000a0;E167K are listed in <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full">http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full</ext-link>. Baseline HbA1c levels were similar across the genotypes, while the duration of diabetes was higher in the homozygotes of both <italic>PNPLA3</italic> and <italic>TM6SF2</italic> genotypes. Baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated in <italic>PNPLA3</italic> and <italic>TM6SF2</italic> risk&#x02010;allele carriers in the GLDI study population but not in the GLDJ study population.</p><table-wrap id="hep41171-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Demographics and Patient Characteristics</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th rowspan="2" align="center" valign="bottom" colspan="1">Variable</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Study GLDI<sup>*</sup>
</th><th colspan="3" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Study GLDJ</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
LY2409021/Placebo<break/>
(n = 246)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
LY2409021<break/>
(n = 60)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
Sitagliptin<break/>
(n = 38)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
Placebo<break/>
(n = 60)</th></tr></thead><tbody valign="top"><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">58.10 (8.93)</td><td align="center" valign="top" rowspan="1" colspan="1">57.3 (8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">57.0 (9.0)</td><td align="center" valign="top" rowspan="1" colspan="1">57.6 (7.8)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Sex, female, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">104 (42.30)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (38.3)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (23.7)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (41.7)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">31.30 (4.31)</td><td align="center" valign="top" rowspan="1" colspan="1">32.42 (5.52)</td><td align="center" valign="top" rowspan="1" colspan="1">31.82 (6.10)</td><td align="center" valign="top" rowspan="1" colspan="1">31.11 (5.12)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Diabetes duration, years, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">7.00 (5.31)</td><td align="center" valign="top" rowspan="1" colspan="1">12.55 (6.16)</td><td align="center" valign="top" rowspan="1" colspan="1">11.08 (6.66)</td><td align="center" valign="top" rowspan="1" colspan="1">10.60 (6.3)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">HbA1c, %, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">7.29 (0.60)</td><td align="center" valign="top" rowspan="1" colspan="1">8.15 (1.01)</td><td align="center" valign="top" rowspan="1" colspan="1">8.25 (0.94)</td><td align="center" valign="top" rowspan="1" colspan="1">8.31 (0.87)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">ALT, U/L, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">28.69 (18.05)</td><td align="center" valign="top" rowspan="1" colspan="1">27.15 (14.1)</td><td align="center" valign="top" rowspan="1" colspan="1">32.84 (19.97)</td><td align="center" valign="top" rowspan="1" colspan="1">25.20 (14.51)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">HFF, %, mean (SD)<sup>&#x02020;</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">12.51 (8.92)</td><td align="center" valign="top" rowspan="1" colspan="1">15.49 (9.78)</td><td align="center" valign="top" rowspan="1" colspan="1">12.11 (8.92)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Race, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Caucasian</td><td align="center" valign="top" rowspan="1" colspan="1">165 (67.10)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (65.0)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (76.3)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (76.7)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Black</td><td align="center" valign="top" rowspan="1" colspan="1">31 (12.60)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (23.3)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (15.8)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (16.7)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Asian</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2.00)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (6.7)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (5.3)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (6.7)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">American Indian or Alaska native</td><td align="center" valign="top" rowspan="1" colspan="1">36 (14.60)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Ethnicity, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">113 (45.90)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (45.0)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (47.4)</td><td align="center" valign="top" rowspan="1" colspan="1">40 (66.7)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">120 (48.80)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (53.3)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (31.7)</td></tr></tbody></table><table-wrap-foot><fn id="hep41171-note-0003"><p>GLDI was a crossover study and all subjects received LY or placebo in each treatment period, so the demographics of all subjects are reported. <sup>&#x02020;</sup>HFF data were collected only in study GLDJ using noncontrast liver serial MRI.</p></fn><fn id="hep41171-note-0004"><p>Abbreviations: BMI, body mass index; n, number of patients.</p></fn></table-wrap-foot></table-wrap></sec><sec id="hep41171-sec-0011"><title>CLINICAL FINDINGS</title><sec id="hep41171-sec-0012"><title>GLDI</title><p>As reported, LY2409021 treatment lowered HbA1c levels with a least squares mean (LSM) difference of &#x02212;0.49% (<italic>P &#x0003c;</italic> 0.001) versus placebo at 6 weeks in GLDI.<xref rid="hep41171-bib-0009" ref-type="ref">9</xref> Significant increases in aminotransferase levels were observed with LY2409021 treatment (<italic>P &#x0003c;</italic> 0.05 versus placebo). The 24&#x02010;hour mean systolic BP increased, with an LSM difference of 2.26 mm Hg versus placebo (<italic>P &#x0003c;</italic> 0.001). The CFB for serum cholesterol, high density lipoprotein&#x02010;cholesterol, low density lipoprotein&#x02010;cholesterol, and triglyceride levels were significantly higher after the LY2409021 treatment period than after the placebo period at week&#x000a0;6 (<italic>P &#x0003c;</italic> 0.001).</p></sec><sec id="hep41171-sec-0013"><title>GLDJ</title><p>As reported, LY2409021 treatment showed significant HbA1c reductions versus placebo (LSM difference, &#x02013;0.77%; <italic>P &#x0003c;</italic> 0.001) but not versus sitagliptin (&#x02212;0.20%; <italic>P</italic> = 0.383) at 6 months.<xref rid="hep41171-bib-0014" ref-type="ref">14</xref> A significant increase in HFF was seen with LY2409021 versus sitagliptin (LSM difference, 3.72%; <italic>P &#x0003c;</italic> 0.001) and placebo (4.44%; <italic>P &#x0003c;</italic> 0.001), accompanied by significant ALT elevations with LY2409021 versus sitagliptin (6.8 U/L; <italic>P</italic> = 0.039) and placebo (10.7 U/L; <italic>P &#x0003c;</italic> 0.001).</p></sec></sec><sec id="hep41171-sec-0014"><title>ASSOCIATION OF GENETIC POLYMORPHISMS WITH ALT AND HFF</title><p>All SNPs tested were in Hardy&#x02013;Weinberg equilibrium. The effect of SNPs on ALT and HFF was tested in all treatment groups. Because the changes in ALT and HFF were most prominent and significant in patients treated with LY2409021, the results presented here are focused on LY2409021 unless otherwise specified. Eight SNPs from <italic>ADCY3</italic>, <italic>PPARGC1A</italic>, <italic>IGF&#x02010;1</italic>, <italic>PNPLA3,</italic> and <italic>TM6SF2</italic> were tested for association with CFB in ALT levels in both studies and with changes in HFF in GLDJ. The results from these analyses are shown in Fig. <xref rid="hep41171-fig-0001" ref-type="fig">1</xref> and Table <xref rid="hep41171-tbl-0002" ref-type="table-wrap">2</xref>.</p><table-wrap id="hep41171-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Genetic Variants Associated with Hepatic Fat Change from Baseline in Study GLDJ</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th rowspan="3" align="center" valign="bottom" colspan="1"/><th rowspan="3" align="center" valign="bottom" colspan="1">Outcome</th><th rowspan="3" align="center" valign="bottom" colspan="1">
Gene<break/>
(SNP)</th><th rowspan="3" align="center" valign="bottom" colspan="1">Treatment Arm</th><th colspan="2" rowspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom">
Homozygous<break/>
(Reference Allele)</th><th colspan="2" rowspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom">Heterozygous</th><th colspan="2" rowspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom">
Homozygous<break/>
(Alternate Allele)</th><th colspan="4" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">
<italic>P</italic> Value</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Main Effect</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Interaction</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">n</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSM (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">n</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSM (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">n</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSM (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Raw</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adj</th><th align="center" valign="bottom" rowspan="1" colspan="1">Raw</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adj</th></tr></thead><tbody valign="top"><tr valign="top" style="border-bottom:solid 1px #000000"><td rowspan="9" align="left" valign="top" colspan="1"/><td rowspan="9" align="center" valign="top" colspan="1">HFF CFB at 6 months</td><td rowspan="3" align="center" valign="top" colspan="1">
<italic>PPARGC1A</italic>
<break/>
(rs4361373)</td><td align="center" valign="top" rowspan="1" colspan="1">LY</td><td align="char" char="." valign="top" rowspan="1" colspan="1">30</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.7 (2.9, 6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.8 (1.2, 6.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;5.6 (&#x02013;12.5, 1.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.021</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.17</td><td rowspan="3" align="char" char="." valign="top" colspan="1">0.330</td><td rowspan="3" align="char" char="." valign="top" colspan="1">1.00</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">PL</td><td align="char" char="." valign="top" rowspan="1" colspan="1">29</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;0.5 (&#x02013;2.4, 1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;0.5 (&#x02013;3.5, 2.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;1.4 (&#x02013;7.1, 4.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.95</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">SI</td><td align="char" char="." valign="top" rowspan="1" colspan="1">18</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.1 (&#x02013;2.3, 2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.8 (&#x02013;1.9, 5.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;2.6 (&#x02013;9.4, 4.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td rowspan="3" align="center" valign="top" colspan="1">
<italic>PNPLA3</italic>
<break/>
(rs738409) Ile148Met</td><td align="center" valign="top" rowspan="1" colspan="1">LY</td><td align="char" char="." valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.2 (1.2, 5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.6 (2.2, 7.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">8.6 (1.5, 15.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.27</td><td align="left" valign="top" rowspan="1" colspan="1"/><td rowspan="3" align="char" char="." valign="top" colspan="1">0.560</td><td rowspan="3" align="char" char="." valign="top" colspan="1">1.00</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">PL</td><td align="char" char="." valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;0.4 (&#x02013;2.4, 1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;0.6 (&#x02013;3.1, 2.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;1.2 (&#x02013;6.1, 3.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.95</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">SI</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;1.2 (&#x02013;4.2, 1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.7 (&#x02013;1.2, 4.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.4 (&#x02013;4.7, 5.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.40</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td rowspan="3" align="center" valign="top" colspan="1">
<italic>TM6SF2</italic>
<break/>
(rs58542926) Glu167Lys</td><td align="center" valign="top" rowspan="1" colspan="1">LY</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.4 (1.9, 5.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.8 (3.0, 10.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.89</td><td rowspan="3" align="char" char="." valign="top" colspan="1">0.500</td><td rowspan="3" align="char" char="." valign="top" colspan="1">1.00</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">PL</td><td align="char" char="." valign="top" rowspan="1" colspan="1">35</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;0.6 (&#x02013;2.3, 1.1)</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02013;0.2 (&#x02013;3.7, 3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.84</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">SI</td><td align="char" char="." valign="top" rowspan="1" colspan="1">21</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.3 (&#x02013;1.9, 2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.5 (&#x02013;3.6, 4.6)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="hep41171-note-0005"><p>Abbreviations: Adj, adjusted <italic>P</italic> value; CI, confidence interval; LY, LY2409021; n, number of samples observed; PL, placebo; Raw, raw <italic>P</italic> value; SI, sitagliptin.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="hep41171-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Association of ALT levels stratified by PNPLA3 (I148M) and TM6SF2 (E167K) genotypes. In both the GLDI and GLDJ studies, ALT levels (change from baseline) are higher in the individuals carrying alternative allele(s) both for PNPLA3 (148M) and TM6SF2 (167K) polymorphisms. (A) Change in ALT levels in GLDI for PNPLA3. (B) Change in ALT levels in GLDJ for PNPLA3. (C) Change in ALT levels in GLDI for TM6SF2. (D) Change in ALT levels in GLDJ for TM6SF2. Abbreviations: E, Glutamate; I, Isoleucine; K, lysine; LY, oral selective glucagon receptor antagonist molecule (LY2409021; 20 mg); M, methionine; PL, placebo; SI, sitagliptin (100 mg).</p></caption><graphic id="nlm-graphic-1" xlink:href="HEP4-2-561-g001"/></fig><p>In GLDI, <italic>PNPLA3</italic> (observed <italic>P</italic> = 0.001, adjusted <italic>P</italic> = 0.005) and <italic>TM6SF2</italic> (observed <italic>P</italic> = 0.001, adjusted <italic>P</italic> = 0.011) SNPs were significantly associated with increases in ALT at 6 weeks in patients treated with LY2409021 but not in the placebo group. In GLDJ, <italic>PNPLA3</italic> (observed <italic>P</italic> = 0.007, adjusted <italic>P</italic> = 0.059) and <italic>PPARGC1A</italic> (rs4361373, observed <italic>P</italic> = 0.003, adjusted <italic>P</italic> = 0.021) SNPs were significantly associated with increased ALT at 6 months in patients treated with LY2409021 but not in the placebo or sitagliptin groups. Heterozygotes for <italic>TM6SF2</italic> E167K had an increase in ALT that was numerically higher but not significant.</p><p>In GLDJ, both PNPLA3 and TM6SF2 risk&#x02010;allele carriers showed increases in HFF that were numerically greater but not significant (Table <xref rid="hep41171-tbl-0002" ref-type="table-wrap">2</xref>). <italic>PPARGC1A</italic> (rs4361373) SNP was nominally associated with a change in HFF (observed <italic>P</italic> = 0.021, adjusted <italic>P</italic> = 0.17) but did not retain statistical significance after adjustment for multiplicity corrections (Table <xref rid="hep41171-tbl-0002" ref-type="table-wrap">2</xref>).</p><p>We subsequently explored the joint effect of <italic>PNPLA3</italic> and <italic>TM6SF2</italic> SNPs on increases in ALT and HFF (Fig. <xref rid="hep41171-fig-0002" ref-type="fig">2</xref>; Table <xref rid="hep41171-tbl-0003" ref-type="table-wrap">3</xref>). Patients who carry at least one copy of the methionine (M) or lysine (K) allele from PNPLA3 and TM6SF2 SNPs were classified as carriers; those who do not carry M/K alleles were classified as noncarriers. In GLDI, carriers showed an ALT increase of 13.28 &#x000b1; 1.17 U/L, while the change in noncarriers was 4.84 &#x000b1; 1.64 U/L (<italic>P</italic> = 4 &#x000d7; 10<sup>&#x02013;5</sup>). Similar to GLDI, in GLDJ, ALT and HFF changes were significantly higher in carriers treated with LY2409021 but not in those receiving placebo or sitagliptin. Carriers showed an ALT increase of 14.57 &#x000b1; 2.79 U/L, while the change in noncarriers was 1.68 &#x000b1; 2.87 U/L (<italic>P</italic> = 0.002). For HFF, carriers showed 5.35% &#x000b1; 1.01% increase, while the increase in noncarriers was 2.38% &#x000b1; 1.06% (<italic>P</italic> = 0.048) (Table <xref rid="hep41171-tbl-0003" ref-type="table-wrap">3</xref>). Because weight gain was observed in patients treated with glucagon receptor antagonist in the GLDJ study, we analyzed for the possible association of PNPLA3 and TM6SF2 variants on weight CFB. No significant association was observed (data not shown) between weight change and the SNPs in either study, suggesting that the association observed with ALT/AST may be independent of weight change. We also analyzed the variability of ALT and HFF CFB explained by the SNPs, and the results are shown in <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full">http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full</ext-link>. PNPLA3 I148M explained more variability in ALT and HFF CFB in general.</p><table-wrap id="hep41171-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Combined Effect of <italic>PNPLA3</italic> I148M and <italic>TM6SF2</italic> E167K on Changes in Transaminases and Hepatic Fat Fraction</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th rowspan="2" align="center" valign="bottom" colspan="1">Study</th><th rowspan="2" align="center" valign="bottom" colspan="1">Endpoint</th><th rowspan="2" align="center" valign="bottom" colspan="1">Treatment</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Noncarriers</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Carriers</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">
<italic>P</italic> Value</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">n</th><th align="center" valign="bottom" rowspan="1" colspan="1">LS Mean &#x000b1; SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">n</th><th align="center" valign="bottom" rowspan="1" colspan="1">LS Mean &#x000b1; SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">Model 1<xref ref-type="fn" rid="hep41171-note-0006">a</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Model 2<xref ref-type="fn" rid="hep41171-note-0007">b</xref>
</th></tr></thead><tbody valign="top"><tr valign="top" style="border-bottom:solid 1px #000000"><td rowspan="2" align="left" valign="top" colspan="1">GLDI</td><td rowspan="2" align="center" valign="top" colspan="1">ALT</td><td align="center" valign="top" rowspan="1" colspan="1">LY2409021</td><td align="char" char="." valign="top" rowspan="1" colspan="1">77</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">4.837 &#x000b1; 1.635</td><td align="char" char="." valign="top" rowspan="1" colspan="1">148</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">13.280 &#x000b1; 1.175</td><td align="center" valign="top" rowspan="1" colspan="1">4 &#x000d7; 10<sup>&#x02013;5</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 &#x000d7; 10<sup>&#x02013;5</sup>
</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">Placebo</td><td align="char" char="." valign="top" rowspan="1" colspan="1">76</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;1.0312 &#x000b1; 1.645</td><td align="char" char="." valign="top" rowspan="1" colspan="1">143</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;1.185 &#x000b1; 1.192</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.939</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.976</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td rowspan="6" align="left" valign="top" colspan="1">GLDJ</td><td rowspan="3" align="center" valign="top" colspan="1">ALT</td><td align="center" valign="top" rowspan="1" colspan="1">LY2409021</td><td align="char" char="." valign="top" rowspan="1" colspan="1">24</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">1.680 &#x000b1; 2.867</td><td align="char" char="." valign="top" rowspan="1" colspan="1">25</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">14.571 &#x000b1; 2.791</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">3 &#x000d7; 10<sup>&#x02013;4</sup>
</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">Placebo</td><td align="char" char="." valign="top" rowspan="1" colspan="1">19</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;4.462 &#x000b1; 3.211</td><td align="char" char="." valign="top" rowspan="1" colspan="1">26</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;2.974 &#x000b1; 2.730</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.724</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.284</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">Sitagliptin</td><td align="char" char="." valign="top" rowspan="1" colspan="1">14</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;1.367 &#x000b1; 3.715</td><td align="char" char="." valign="top" rowspan="1" colspan="1">19</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;0.463 &#x000b1; 3.194</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.854</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.693</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td rowspan="3" align="center" valign="top" colspan="1">HFF</td><td align="center" valign="top" rowspan="1" colspan="1">LY2409021</td><td align="char" char="." valign="top" rowspan="1" colspan="1">22</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.384 &#x000b1; 1.062</td><td align="char" char="." valign="top" rowspan="1" colspan="1">24</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">5.353 &#x000b1; 1.005</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.048</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.021</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">Placebo</td><td align="char" char="." valign="top" rowspan="1" colspan="1">17</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;0.729 &#x000b1; 1.190</td><td align="char" char="." valign="top" rowspan="1" colspan="1">26</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;0.470 &#x000b1; 0.960</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.865</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.850</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="center" valign="top" rowspan="1" colspan="1">Sitagliptin</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">&#x02013;1.868 &#x000b1; 1.560</td><td align="char" char="." valign="top" rowspan="1" colspan="1">18</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">1.359 &#x000b1; 1.151</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.099</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.325</td></tr></tbody></table><table-wrap-foot><fn id="hep41171-note-0006"><label>a</label><p>Model 1, linear model that uses carrier status defined by carriage of at least one minor allele of <italic>PNPLA3</italic> or <italic>TM6SF2</italic> SNPs as the covariate of main interest.</p></fn><fn id="hep41171-note-0007"><label>b</label><p>Model 2, linear model that uses allele dosage defined as the sum of the risk allele counts from the <italic>PNPLA3</italic> and <italic>TM6SF2</italic> SNPs as the covariate.</p></fn><fn id="hep41171-note-0008"><p>Abbreviations: LS, least squares; n, number of subjects.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="hep41171-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Relationship between <italic>PNPLA3</italic> (I148M) and <italic>TM6SF2</italic> (E167K) SNPs and aminotransferases and HFF in GLDI and GLDJ studies. All patients were classified as carriers if they carry at least one copy of the risk allele (i.e., methionine for PNPLA3, and/or lysine for TM6SF2). All other patients were defined as noncarriers (statistical significance is shown for Model 1). Evaluation for the additive effects of the risk alleles was also performed for both SNPs (Model 2; see Table <xref rid="hep41171-tbl-0003" ref-type="table-wrap">3</xref>). (A) Change in ALT levels (from baseline at 6 weeks) in risk&#x02010;allele carriers versus noncarriers in GLDI. (B) Change in AST levels (from baseline at 6 weeks) in risk&#x02010;allele carriers versus noncarriers in GLDI. (C) Change in ALT levels (from baseline at 6 months) in risk&#x02010;allele carriers versus noncarriers in GLDJ. (D) Change in AST levels (from baseline at 6 months) in risk&#x02010;allele carriers versus noncarriers in GLDJ. (E) Change in HFF (from baseline at 6 months) in risk&#x02010;allele carriers versus noncarriers in GLDJ. Abbreviations: K, lysine; LY, oral selective glucagon receptor antagonist molecule (LY2409021; 20 mg); M, methionine; PL, placebo; SI, sitagliptin (100 mg).</p></caption><graphic id="nlm-graphic-3" xlink:href="HEP4-2-561-g002"/></fig></sec></sec><sec id="hep41171-sec-0015"><title>Discussion</title><p>LY2409021is a novel glucagon receptor antagonist with a significant glucose&#x02010;lowering effect in patients with T2D but was unexpectedly associated with increases in aminotransferases and hepatic fat in phase 2 clinical trials.<xref rid="hep41171-bib-0014" ref-type="ref">14</xref> We investigated if selected genetic variants linked to NAFLD in the general population are associated with hepatic steatosis and elevated ALT levels associated with LY2409021. Our results demonstrate that patients carrying the risk alleles of <italic>PNPLA3</italic>/<italic>TM6SF2</italic> polymorphisms are at a higher risk for serum aminotransferase elevation and hepatic fat accumulation when exposed to LY2409021. These variants did not show any effect on glycemic efficacy endpoints (data not shown).</p><p>The role of <italic>PNPLA3</italic> and <italic>TM6SF2</italic> in NAFLD pathogenesis is not completely understood. <italic>PNPLA3</italic>, also called adiponutrin, encodes a 481&#x02010;amino acid membrane protein localized in the endoplasmic reticulum and at the surface of lipid droplets. In humans, this protein has the highest expression in hepatic stellate cells (HSCs), retina, and hepatocytes. It functions as both a triglyceride hydrolase (suggesting catabolic lipase activity) and acetyl&#x02010;coenzyme A&#x02010;independent transacylase (suggesting anabolic lipogenic activity).<xref rid="hep41171-bib-0023" ref-type="ref">23</xref>, <xref rid="hep41171-bib-0024" ref-type="ref">24</xref>, <xref rid="hep41171-bib-0025" ref-type="ref">25</xref> TM6SF2 is a 377&#x02010;amino acid protein of unknown function. It has broad tissue and organ expression with highest relative levels of expression in the small intestine and liver.<xref rid="hep41171-bib-0018" ref-type="ref">18</xref>, <xref rid="hep41171-bib-0026" ref-type="ref">26</xref> It is speculated that the <italic>PNPLA3</italic> I148M variant is attached on the surface of lipid droplets, reducing triglyceride breakdown leading to lipid retention in the hepatocyte lipid droplet, while the TM6SF2 E167K variant reduces triglyceride secretion through very low&#x02010;density lipoprotein, leading to hepatocellular retention of lipids.<xref rid="hep41171-bib-0027" ref-type="ref">27</xref>, <xref rid="hep41171-bib-0028" ref-type="ref">28</xref>, <xref rid="hep41171-bib-0029" ref-type="ref">29</xref> PNPLA3 also has a role in HSCs and retinol metabolism. PNPLA3 is shown to have retinyl&#x02010;palmitate lipase activity in HSCs, and the I148M mutation leads to a loss of this function.<xref rid="hep41171-bib-0030" ref-type="ref">30</xref>, <xref rid="hep41171-bib-0031" ref-type="ref">31</xref> Retinyl&#x02010;palmitate content is elevated and the ratio of retinol/retinyl&#x02010;palmitate was reduced in liver extracts from patients with the homozygous variant genotype of PNPLA3 I148M.<xref rid="hep41171-bib-0032" ref-type="ref">32</xref> The interaction of these variants with glucagon receptor signaling is not clear.</p><p>The mechanism for HFF accumulation and increases in hepatic aminotransferase levels by blocking the glucagon receptor remains to be determined. Glucagon exerts hypolipidemic actions in rats,<xref rid="hep41171-bib-0033" ref-type="ref">33</xref> and subcutaneous glucagon administration promotes mobilization of hepatic fat in lactating dairy cows.<xref rid="hep41171-bib-0034" ref-type="ref">34</xref> The hypolipidemic actions of glucagon on hepatocytes is, in part, through a PPAR&#x003b1;&#x02010;dependent pathway.<xref rid="hep41171-bib-0004" ref-type="ref">4</xref> Accelerated development of steatosis was observed in studies with high&#x02010;fat feeding in glucagon receptor (GCGR)<sup>&#x02013;/&#x02013;</sup> mice.<xref rid="hep41171-bib-0004" ref-type="ref">4</xref> These observations in multiple animal species together with the novel findings reported in humans<xref rid="hep41171-bib-0004" ref-type="ref">4</xref> imply that a threshold level of GCGR signaling might be required for hepatocytes to maintain their metabolic regulatory function. If this is the case, marked attenuation of GCGR signaling by glucagon receptor antagonism could lead to increased risk of developing dyslipidemia and fatty liver.</p><p>Glucagon receptor antagonist treatment may have a potentiating effect in patients who are genetically predisposed to dysregulation of liver lipid metabolism, leading to elevated lipid accumulation. These results show that patients who carry the risk alleles of either PNPLA3 or TM6SF2 are at higher risk of the hepatic side effects of a glucagon receptor antagonist. The hepatic lipid accumulation effect of glucagon receptor antagonism can also be observed in nonrisk&#x02010;allele carriers; however, the severity of this effect may be much higher in risk&#x02010;allele carriers. The exact mechanism behind this effect is not entirely clear, and it is possible that one or both of these gene products may be directly involved in mediating the known effect of glucagon on hepatic lipid metabolism.</p><p>The role of PNPLA3 and TM6SF2 polymorphisms on susceptibility to NAFLD is widely reported. However, the effect of these variants on treatment response is poorly understood. It has recently been reported that PNPLA3 rs738409 variant explained 3.8% of the variability in ALT in remission induction therapy for acute lymphoblastic leukemia.<xref rid="hep41171-bib-0035" ref-type="ref">35</xref> The same variant also has been shown to be associated with significant increases in ALT, AST, and hepatic fat in T2D patients treated with a hepatopreferential insulin, basal insulin peglispro, but not with insulin glargine.<xref rid="hep41171-bib-0036" ref-type="ref">36</xref> In this report, we present a further role of these variants in treatment response in patients with T2D.</p><p>Our study has several strengths, including genetic analyses in two independent randomized clinical trials with reasonable sample size to test our hypotheses. To our knowledge, this is the first study to evaluate the genetic basis for drug&#x02010;induced hepatic steatosis and related aminotransferase elevations.</p><p>A few limitations of our study are noteworthy. First, we limited our analyses to a few candidate SNPs, and two other NASH/NAFLD loci with replicated evidence of association in the literature (glucokinase regulator [<italic>GCKR</italic>] and membrane bound O&#x02010;acyltransferase domain&#x02010;containing 7&#x02013; transmembrane channel like 4 [<italic>MBOAT7&#x02010;TMC4</italic>])<xref rid="hep41171-bib-0020" ref-type="ref">20</xref>, <xref rid="hep41171-bib-0037" ref-type="ref">37</xref>, <xref rid="hep41171-bib-0038" ref-type="ref">38</xref>, <xref rid="hep41171-bib-0039" ref-type="ref">39</xref> are not included in this analysis. We conducted post&#x02010;hoc analyses of the effect of the sentinel SNPs in <italic>GCKR</italic> (rs780094) and <italic>MBOAT7&#x02010;TMC4</italic> (rs2576452, which is in strong linkage disequilibrium with rs641738) on HFF and ALT and did not find any significant meaningful associations (data not shown). Although we have generated genome&#x02010;wide genotyping data, we have not attempted a traditional genome&#x02010;wide association study due to sample size limitations. Furthermore, single&#x02010;variant analyses of <italic>PNPLA3</italic> and <italic>TM6SF2</italic> did not yield significant association with liver fat change at 6 months. The variability of the HFF measurements (indicated by wider confidence intervals) could be one of the reasons. The allele frequency of the TM6SF2 variant was low, and more subjects may be needed to obtain conclusive evidence. However, because both the studied variants are well&#x02010;established genetic markers for the liver&#x02010;related traits, we thus capitalized the opportunity to model the joint effect of the two SNPs on liver enzyme elevation and hepatic fat accumulation. Given the low frequency of risk allele along with lower counts for the GLDJ study, this approach is more meaningful if the genetic effect of TM6SF2 is captured along with PNPLA3 in the joint analyses. Moreover, only one of the studies measured hepatic fat data; it would be helpful to have these results confirmed in other independent settings. Nevertheless, it is worth noting that the hepatic aminotransferase elevations were consistent in both studies with short&#x02010;term (6 weeks) exposure as well as long&#x02010;term exposure (6 months). Because our investigations are limited to LY2409021 phase 2 studies, it is unknown if the observed association between <italic>PNPLA3</italic> and <italic>TM6SF2</italic> variants and drug&#x02010;induced hepatic steatosis is generalizable to other glucagon receptor antagonists or to other drugs, such as mipomersen, lomitapide, or pegylated insulin lispro, which recently have been described to cause hepatic steatosis. Finally, because this is a retrospective pharmacogenetics analysis, the randomization based on genotypes was not possible.</p><p>In conclusion, it appears that carriers of <italic>PNPLA3</italic> and <italic>TM6SF2</italic> variant alleles are at risk for hepatic steatosis and elevated ALT levels caused by LY2409021, a novel glucagon receptor antagonist. It is unclear if this genetic predisposition is a class effect of glucagon receptor antagonists or specific to LY2409021. If confirmed, our observations may be used to investigate glucagon receptor antagonists specifically among individuals without at&#x02010;risk <italic>PNPLA3</italic> and <italic>TM6SF2</italic> alleles.</p></sec><sec id="hep41171-sec-0127"><p>Author names in bold designate shared co&#x02010;first authorship.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><p>Additional Supporting Information may be found at <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full">http://onlinelibrary.wiley.com/doi/10.1002/hep4.1171/full</ext-link>.</p></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supplementary Table 1. Study Design for Phase 2 GLDI and GLDJ Studies with LY2409021 in Type 2 Diabetes</p><p>Supplementary Table 2: Baseline Demographics and Patient Characteristics Based on the Genotype for PNPLA3 I148M and TM6SF2 E167K.</p><p>Supplementary Table&#x02010;3: Proportion of genetic variance explained by PNPLA3 and TM6SF2 Variants for ALT and HFF (CFB)</p></caption><media xlink:href="HEP4-2-561-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references"><title>REFERENCES</title><ref id="hep41171-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="hep41171-cit-0001">
<string-name>
<surname>Sloop</surname>
<given-names>KW</given-names>
</string-name>, 
<string-name>
<surname>Michael</surname>
<given-names>MD</given-names>
</string-name>, 
<string-name>
<surname>Moyers</surname>
<given-names>JS</given-names>
</string-name>. <article-title>Glucagon as a target for the treatment of type 2 diabetes</article-title>. <source>Expert Opin Ther Targets</source>
<year>2005</year>;<volume>9</volume>:<fpage>593</fpage>&#x02010;<lpage>600</lpage>.
<pub-id pub-id-type="pmid">15948676</pub-id></mixed-citation></ref><ref id="hep41171-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="hep41171-cit-0002">
<string-name>
<surname>Unger</surname>
<given-names>RH</given-names>
</string-name>, 
<string-name>
<surname>Cherrington</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover</article-title>. <source>J Clin Invest</source>
<year>2012</year>;<volume>122</volume>:<fpage>4</fpage>&#x02010;<lpage>12</lpage>.
<pub-id pub-id-type="pmid">22214853</pub-id></mixed-citation></ref><ref id="hep41171-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="hep41171-cit-0003">
<string-name>
<surname>Woerle</surname>
<given-names>HJ</given-names>
</string-name>, 
<string-name>
<surname>Szoke</surname>
<given-names>E</given-names>
</string-name>, 
<string-name>
<surname>Meyer</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Dostou</surname>
<given-names>JM</given-names>
</string-name>, 
<string-name>
<surname>Wittlin</surname>
<given-names>SD</given-names>
</string-name>, 
<string-name>
<surname>Gosmanov</surname>
<given-names>NR</given-names>
</string-name>, et al. <article-title>Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2006</year>;<volume>290</volume>:<fpage>E67</fpage>&#x02010;<lpage>E77</lpage>.
<pub-id pub-id-type="pmid">16105859</pub-id></mixed-citation></ref><ref id="hep41171-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="hep41171-cit-0004">
<string-name>
<surname>Ali</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Drucker</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2009</year>;<volume>296</volume>:<fpage>E415</fpage>&#x02010;<lpage>E421</lpage>.
<pub-id pub-id-type="pmid">19116373</pub-id></mixed-citation></ref><ref id="hep41171-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="hep41171-cit-0005">
<string-name>
<surname>Sammons</surname>
<given-names>MF</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>
<given-names>EC</given-names>
</string-name>. <article-title>Recent progress in the development of small&#x02010;molecule glucagon receptor antagonists</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2015</year>;<volume>25</volume>:<fpage>4057</fpage>&#x02010;<lpage>4064</lpage>.
<pub-id pub-id-type="pmid">26271588</pub-id></mixed-citation></ref><ref id="hep41171-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="hep41171-cit-0006">
<string-name>
<surname>Bergman</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Tan</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Somayaji</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>Calle</surname>
<given-names>RA</given-names>
</string-name>, 
<string-name>
<surname>Kazierad</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Assessment of PF&#x02010;06291874 (PF), a glucagon receptor antagonist administered as monotherapy for four weeks in patients with type 2 diabetes mellitus (T2DM) [Abstract]</article-title>. <source>Diabetes</source>
<year>2016</year>;<volume>65</volume>(<issue>Suppl. 1</issue>):<fpage>1084</fpage>&#x02010;P. <ext-link ext-link-type="uri" xlink:href="http://www.abstractsonline.com/pp8/#!/4008/presentation/25548">http://www.abstractsonline.com/pp8/#!/4008/presentation/25548</ext-link>
</mixed-citation></ref><ref id="hep41171-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="hep41171-cit-0007">
<string-name>
<surname>Engel</surname>
<given-names>SS</given-names>
</string-name>, 
<string-name>
<surname>Xu</surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname>Andryuk</surname>
<given-names>PJ</given-names>
</string-name>, 
<string-name>
<surname>Davies</surname>
<given-names>MJ</given-names>
</string-name>, 
<string-name>
<surname>Amatruda</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Kaufman</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Efficacy and tolerability of MK&#x02010;0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM) [Abstract]</article-title>. <source>Diabetes</source>
<year>2011</year>;<volume>60</volume>(<issue>Suppl. 1</issue>):<fpage>A85</fpage>
<ext-link ext-link-type="uri" xlink:href="https://professional.diabetes.org/abstract/efficacy-and-tolerability-mk-0893-glucagon-receptor-antagonist-gra-patients-type-2-diabetes">https://professional.diabetes.org/abstract/efficacy-and-tolerability-mk-0893-glucagon-receptor-antagonist-gra-patients-type-2-diabetes</ext-link>
</mixed-citation></ref><ref id="hep41171-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="hep41171-cit-0008">
<string-name>
<surname>Kazda</surname>
<given-names>CM</given-names>
</string-name>, 
<string-name>
<surname>Ding</surname>
<given-names>Y</given-names>
</string-name>, 
<string-name>
<surname>Kelly</surname>
<given-names>RP</given-names>
</string-name>, 
<string-name>
<surname>Garhyan</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Shi</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Lim</surname>
<given-names>CN</given-names>
</string-name>, et al. <article-title>Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12&#x02010; and 24&#x02010;week phase 2 studies</article-title>. <source>Diabetes Care</source>
<year>2016</year>;<volume>39</volume>:<fpage>1241</fpage>&#x02010;<lpage>1249</lpage>. Erratum in: Diabetes Care 2017;40:808.
<pub-id pub-id-type="pmid">26681715</pub-id></mixed-citation></ref><ref id="hep41171-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="hep41171-cit-0009">
<string-name>
<surname>Kazda</surname>
<given-names>CM</given-names>
</string-name>, 
<string-name>
<surname>Frias</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Foga</surname>
<given-names>I</given-names>
</string-name>, 
<string-name>
<surname>Cui</surname>
<given-names>X</given-names>
</string-name>, 
<string-name>
<surname>Guzman</surname>
<given-names>CB</given-names>
</string-name>, 
<string-name>
<surname>Garhyan</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>
<year>2017</year>;<volume>19</volume>:<fpage>1071</fpage>&#x02010;<lpage>1077</lpage>.
<pub-id pub-id-type="pmid">28191913</pub-id></mixed-citation></ref><ref id="hep41171-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="hep41171-cit-0010">
<string-name>
<surname>Kazierad</surname>
<given-names>DJ</given-names>
</string-name>, 
<string-name>
<surname>Bergman</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Tan</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Erion</surname>
<given-names>DM</given-names>
</string-name>, 
<string-name>
<surname>Somayaji</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>
<given-names>DS</given-names>
</string-name>, et al. <article-title>Effects of multiple ascending doses of the glucagon receptor antagonist PF&#x02010;06291874 in patients with type 2 diabetes mellitus</article-title>. <source>Diabetes Obes Metab</source>
<year>2016</year>;<volume>18</volume>:<fpage>795</fpage>&#x02010;<lpage>802</lpage>.
<pub-id pub-id-type="pmid">27059951</pub-id></mixed-citation></ref><ref id="hep41171-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="hep41171-cit-0011">
<string-name>
<surname>Morgan</surname>
<given-names>E</given-names>
</string-name>, 
<string-name>
<surname>Smith</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Watts</surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname>Xia</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Cheng</surname>
<given-names>W</given-names>
</string-name>, 
<string-name>
<surname>Geary</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>ISIS&#x02010;GCGRRX, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy [Abstract]</article-title>. <source>Diabetes</source>
<year>2014</year>;<volume>63</volume>(<issue>Suppl. 1</issue>):<fpage>LB28</fpage>
<ext-link ext-link-type="uri" xlink:href="http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=a40c1c80-02c8-4eb5-bdff-5e4c81cf9cf5&#x00026;cKey=162316ab-e524-43be-87a1-3cc488c12086&#x00026;mKey=%7b40FC5C61-819A-4D1B-AABA-3705F7D0EA76%7d#">http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=a40c1c80-02c8-4eb5-bdff-5e4c81cf9cf5&#x00026;cKey=162316ab-e524-43be-87a1-3cc488c12086&#x00026;mKey=%7b40FC5C61-819A-4D1B-AABA-3705F7D0EA76%7d#</ext-link>
</mixed-citation></ref><ref id="hep41171-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="hep41171-cit-0012">
<string-name>
<surname>Ruddy</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Pramanik</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Lunceford</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Cilissen</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Stoch</surname>
<given-names>SA</given-names>
</string-name>, et al. <article-title>Inhibition of glucagon&#x02010;induced hyperglycemia predicts glucose lowering efficacy of a glucagon receptor antagonist, MK&#x02010;0893, in type 2 diabetes (T2DM) [Abstract]</article-title>. <source>Diabetes</source>
<year>2011</year>;<volume>60</volume>(<issue>Suppl. 1</issue>):<fpage>A85</fpage>&#x02010;<lpage>A86</lpage>. <ext-link ext-link-type="uri" xlink:href="https://professional.diabetes.org/abstract/inhibition-glucagonndashinduced-hyperglycemia-predicts-glucose-lowering-efficacy-glucagon">https://professional.diabetes.org/abstract/inhibition-glucagonndashinduced-hyperglycemia-predicts-glucose-lowering-efficacy-glucagon</ext-link>
</mixed-citation></ref><ref id="hep41171-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="hep41171-cit-0013">
<string-name>
<surname>Vajda</surname>
<given-names>EG</given-names>
</string-name>, 
<string-name>
<surname>Logan</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Lasseter</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>Armas</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Plotkin</surname>
<given-names>DJ</given-names>
</string-name>, 
<string-name>
<surname>Pipkin</surname>
<given-names>JD</given-names>
</string-name>, et al. <article-title>Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD&#x02010;6972 in healthy subjects and subjects with type 2 diabetes mellitus</article-title>. <source>Diabetes Obes Metab</source>
<year>2017</year>;<volume>19</volume>:<fpage>24</fpage>&#x02010;<lpage>32</lpage>.
<pub-id pub-id-type="pmid">27501510</pub-id></mixed-citation></ref><ref id="hep41171-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="hep41171-cit-0014">
<string-name>
<surname>Guzman</surname>
<given-names>CB</given-names>
</string-name>, 
<string-name>
<surname>Zhang</surname>
<given-names>XM</given-names>
</string-name>, 
<string-name>
<surname>Liu</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Regev</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Shankar</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Garhyan</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>
<year>2017</year>;<volume>19</volume>:<fpage>1521</fpage>&#x02010;<lpage>1528</lpage>.
<pub-id pub-id-type="pmid">28371155</pub-id></mixed-citation></ref><ref id="hep41171-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="hep41171-cit-0015">
<string-name>
<surname>Guerrero</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Vega</surname>
<given-names>GL</given-names>
</string-name>, 
<string-name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</string-name>, 
<string-name>
<surname>Browning</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Ethnic differences in hepatic steatosis: an insulin resistance paradox?</article-title>
<source>Hepatology</source>
<year>2009</year>;<volume>49</volume>:<fpage>791</fpage>&#x02010;<lpage>801</lpage>.
<pub-id pub-id-type="pmid">19105205</pub-id></mixed-citation></ref><ref id="hep41171-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="hep41171-cit-0016">
<string-name>
<surname>Schwimmer</surname>
<given-names>JB</given-names>
</string-name>, 
<string-name>
<surname>Celedon</surname>
<given-names>MA</given-names>
</string-name>, 
<string-name>
<surname>Lavine</surname>
<given-names>JE</given-names>
</string-name>, 
<string-name>
<surname>Salem</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Campbell</surname>
<given-names>N</given-names>
</string-name>, 
<string-name>
<surname>Schork</surname>
<given-names>NJ</given-names>
</string-name>, et al. <article-title>Heritability of nonalcoholic fatty liver disease</article-title>. <source>Gastroenterology</source>
<year>2009</year>;<volume>136</volume>:<fpage>1585</fpage>&#x02010;<lpage>1592</lpage>.
<pub-id pub-id-type="pmid">19208353</pub-id></mixed-citation></ref><ref id="hep41171-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="hep41171-cit-0017">
<string-name>
<surname>Gorden</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Yerges&#x02010;Armstrong</surname>
<given-names>LM</given-names>
</string-name>, 
<string-name>
<surname>Ryan</surname>
<given-names>KA</given-names>
</string-name>, 
<string-name>
<surname>Speliotes</surname>
<given-names>E</given-names>
</string-name>, 
<string-name>
<surname>Borecki</surname>
<given-names>IB</given-names>
</string-name>, et al.; <collab collab-type="authors">GOLD Consortium</collab>
. <article-title>Genetic variation at NCAN locus is associated with inflammation and fibrosis in non&#x02010;alcoholic fatty liver disease in morbid obesity</article-title>. <source>Hum Hered</source>
<year>2013</year>;<volume>75</volume>:<fpage>34</fpage>&#x02010;<lpage>43</lpage>.
<pub-id pub-id-type="pmid">23594525</pub-id></mixed-citation></ref><ref id="hep41171-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="hep41171-cit-0018">
<string-name>
<surname>Kozlitina</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Smagris</surname>
<given-names>E</given-names>
</string-name>, 
<string-name>
<surname>Stender</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>, 
<string-name>
<surname>Zhou</surname>
<given-names>HH</given-names>
</string-name>, 
<string-name>
<surname>Tybjaerg&#x02010;Hansen</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Exome&#x02010;wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease</article-title>. <source>Nat Genet</source>
<year>2014</year>;<volume>46</volume>:<fpage>352</fpage>&#x02010;<lpage>356</lpage>.
<pub-id pub-id-type="pmid">24531328</pub-id></mixed-citation></ref><ref id="hep41171-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="hep41171-cit-0019">
<string-name>
<surname><bold>Romeo</bold></surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname><bold>Kozlitina</bold></surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Xing</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Pertsemlidis</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Cox</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Pennacchio</surname>
<given-names>LA</given-names>
</string-name>, et al. <article-title>Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease</article-title>. <source>Nat Genet</source>
<year>2008</year>;<volume>40</volume>:<fpage>1461</fpage>&#x02010;<lpage>1465</lpage>.
<pub-id pub-id-type="pmid">18820647</pub-id></mixed-citation></ref><ref id="hep41171-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="hep41171-cit-0020">
<string-name>
<surname><bold>Speliotes</bold></surname>
<given-names>EK</given-names>
</string-name>, 
<string-name>
<surname><bold>Yerges&#x02010;Armstrong</bold></surname>
<given-names>LM</given-names>
</string-name>, 
<string-name>
<surname><bold>Wu</bold></surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname><bold>Hernaez</bold></surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname><bold>Kim</bold></surname>
<given-names>LJ</given-names>
</string-name>, 
<string-name>
<surname>Palmer</surname>
<given-names>CD</given-names>
</string-name>, et al.; <collab collab-type="authors">GOLD Consortium</collab>
. <article-title>Genome&#x02010;wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits</article-title>. <source>PLoS Genet</source>
<year>2011</year>;<volume>7</volume>:<fpage>e1001324</fpage>.
<pub-id pub-id-type="pmid">21423719</pub-id></mixed-citation></ref><ref id="hep41171-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="hep41171-cit-0021">
<string-name>
<surname>Dongiovanni</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Donati</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Fares</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Lombardi</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Mancina</surname>
<given-names>RM</given-names>
</string-name>, 
<string-name>
<surname>Romeo</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>PNPLA3 I148M polymorphism and progressive liver disease</article-title>. <source>World J Gastroenterol</source>
<year>2013</year>;<volume>19</volume>:<fpage>6969</fpage>&#x02010;<lpage>6978</lpage>.
<pub-id pub-id-type="pmid">24222941</pub-id></mixed-citation></ref><ref id="hep41171-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="hep41171-cit-0022">
<string-name>
<surname>Trepo</surname>
<given-names>E</given-names>
</string-name>, 
<string-name>
<surname>Romeo</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Zucman&#x02010;Rossi</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Nahon</surname>
<given-names>P</given-names>
</string-name>. <article-title>PNPLA3 gene in liver diseases</article-title>. <source>J Hepatol</source>
<year>2016</year>;<volume>65</volume>:<fpage>399</fpage>&#x02010;<lpage>412</lpage>.
<pub-id pub-id-type="pmid">27038645</pub-id></mixed-citation></ref><ref id="hep41171-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="hep41171-cit-0023">
<string-name>
<surname>He</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>McPhaul</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>
<given-names>JZ</given-names>
</string-name>, 
<string-name>
<surname>Garuti</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Kinch</surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname>Grishin</surname>
<given-names>NV</given-names>
</string-name>, et al. <article-title>A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis</article-title>. <source>J Biol Chem</source>
<year>2010</year>;<volume>285</volume>:<fpage>6706</fpage>&#x02010;<lpage>6715</lpage>.
<pub-id pub-id-type="pmid">20034933</pub-id></mixed-citation></ref><ref id="hep41171-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="hep41171-cit-0024">
<string-name>
<surname>Kumari</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Schoiswohl</surname>
<given-names>G</given-names>
</string-name>, 
<string-name>
<surname>Chitraju</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Paar</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Cornaciu</surname>
<given-names>I</given-names>
</string-name>, 
<string-name>
<surname>Rangrez</surname>
<given-names>AY</given-names>
</string-name>, et al. <article-title>Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase</article-title>. <source>Cell Metab</source>
<year>2012</year>;<volume>15</volume>:<fpage>691</fpage>&#x02010;<lpage>702</lpage>.
<pub-id pub-id-type="pmid">22560221</pub-id></mixed-citation></ref><ref id="hep41171-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="hep41171-cit-0025">
<string-name>
<surname><bold>Pingitore</bold></surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname><bold>Pirazzi</bold></surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Mancina</surname>
<given-names>RM</given-names>
</string-name>, 
<string-name>
<surname>Motta</surname>
<given-names>BM</given-names>
</string-name>, 
<string-name>
<surname>Indiveri</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Pujia</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function</article-title>. <source>Biochim Biophys Acta</source>
<year>2014</year>;<volume>1841</volume>:<fpage>574</fpage>&#x02010;<lpage>580</lpage>.
<pub-id pub-id-type="pmid">24369119</pub-id></mixed-citation></ref><ref id="hep41171-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="hep41171-cit-0026">
<string-name>
<surname><bold>O'Hare</bold></surname>
<given-names>EA</given-names>
</string-name>, 
<string-name>
<surname><bold>Yang</bold></surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Yerges&#x02010;Armstrong</surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname>Sreenivasan</surname>
<given-names>U</given-names>
</string-name>, 
<string-name>
<surname>McFarland</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Leitch</surname>
<given-names>CC</given-names>
</string-name>, et al. <article-title>TM6SF2 rs58542926 impacts lipid processing in liver and small intestine</article-title>. <source>Hepatology</source>
<year>2017</year>;<volume>65</volume>:<fpage>1526</fpage>&#x02010;<lpage>1542</lpage>.
<pub-id pub-id-type="pmid">28027591</pub-id></mixed-citation></ref><ref id="hep41171-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="hep41171-cit-0027">
<string-name>
<surname>Dongiovanni</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Romeo</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Valenti</surname>
<given-names>L</given-names>
</string-name>. <article-title>Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis</article-title>. <source>Biomed Res Int</source>
<year>2015</year>;<volume>2015</volume>:<fpage>460190</fpage>.
<pub-id pub-id-type="pmid">26273621</pub-id></mixed-citation></ref><ref id="hep41171-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="hep41171-cit-0028">
<string-name>
<surname><bold>Pirazzi</bold></surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname><bold>Adiels</bold></surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Burza</surname>
<given-names>MA</given-names>
</string-name>, 
<string-name>
<surname>Mancina</surname>
<given-names>RM</given-names>
</string-name>, 
<string-name>
<surname>Levin</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Stahlman</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Patatin&#x02010;like phospholipase domain&#x02010;containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro</article-title>. <source>J Hepatol</source>
<year>2012</year>;<volume>57</volume>:<fpage>1276</fpage>&#x02010;<lpage>1282</lpage>.
<pub-id pub-id-type="pmid">22878467</pub-id></mixed-citation></ref><ref id="hep41171-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="hep41171-cit-0029">
<string-name>
<surname>Ruhanen</surname>
<given-names>H</given-names>
</string-name>, 
<string-name>
<surname>Perttila</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Holtta&#x02010;Vuori</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, 
<string-name>
<surname>Yki&#x02010;Jarvinen</surname>
<given-names>H</given-names>
</string-name>, 
<string-name>
<surname>Ikonen</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>PNPLA3 mediates hepatocyte triacylglycerol remodeling</article-title>. <source>J Lipid Res</source>
<year>2014</year>;<volume>55</volume>:<fpage>739</fpage>&#x02010;<lpage>746</lpage>.
<pub-id pub-id-type="pmid">24511104</pub-id></mixed-citation></ref><ref id="hep41171-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="hep41171-cit-0030">
<string-name>
<surname><bold>Mondul</bold></surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname><bold>Mancina</bold></surname>
<given-names>RM</given-names>
</string-name>, 
<string-name>
<surname>Merlo</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Dongiovanni</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Rametta</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Montalcini</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>PNPLA3 I148M Variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity</article-title>. <source>J Nutr</source>
<year>2015</year>;<volume>145</volume>:<fpage>1687</fpage>&#x02010;<lpage>1691</lpage>.
<pub-id pub-id-type="pmid">26136587</pub-id></mixed-citation></ref><ref id="hep41171-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="hep41171-cit-0031">
<string-name>
<surname><bold>Pirazzi</bold></surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname><bold>Valenti</bold></surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname><bold>Motta</bold></surname>
<given-names>BM</given-names>
</string-name>, 
<string-name>
<surname>Pingitore</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Hedfalk</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>Mancina</surname>
<given-names>RM</given-names>
</string-name>, et al. <article-title>PNPLA3 has retinyl&#x02010;palmitate lipase activity in human hepatic stellate cells</article-title>. <source>Hum Mol Genet</source>
<year>2014</year>;<volume>23</volume>:<fpage>4077</fpage>&#x02010;<lpage>4085</lpage>.
<pub-id pub-id-type="pmid">24670599</pub-id></mixed-citation></ref><ref id="hep41171-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="hep41171-cit-0032">
<string-name>
<surname>Kovarova</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Konigsrainer</surname>
<given-names>I</given-names>
</string-name>, 
<string-name>
<surname>Konigsrainer</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Machicao</surname>
<given-names>F</given-names>
</string-name>, 
<string-name>
<surname>Haring</surname>
<given-names>HU</given-names>
</string-name>, 
<string-name>
<surname>Schleicher</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl&#x02010;palmitate storage in humans</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2015</year>;<volume>100</volume>:<fpage>E1568</fpage>&#x02010;<lpage>1574</lpage>.
<pub-id pub-id-type="pmid">26439088</pub-id></mixed-citation></ref><ref id="hep41171-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="hep41171-cit-0033">
<string-name>
<surname>Guettet</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Rostaqui</surname>
<given-names>N</given-names>
</string-name>, 
<string-name>
<surname>Mathe</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Lecuyer</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Navarro</surname>
<given-names>N</given-names>
</string-name>, 
<string-name>
<surname>Jacotot</surname>
<given-names>B</given-names>
</string-name>. <article-title>Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol&#x02010;fed rats</article-title>. <source>Lipids</source>
<year>1991</year>;<volume>26</volume>:<fpage>451</fpage>&#x02010;<lpage>458</lpage>.
<pub-id pub-id-type="pmid">1881241</pub-id></mixed-citation></ref><ref id="hep41171-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="hep41171-cit-0034">
<string-name>
<surname>Nafikov</surname>
<given-names>RA</given-names>
</string-name>, 
<string-name>
<surname>Ametaj</surname>
<given-names>BN</given-names>
</string-name>, 
<string-name>
<surname>Bobe</surname>
<given-names>G</given-names>
</string-name>, 
<string-name>
<surname>Koehler</surname>
<given-names>KJ</given-names>
</string-name>, 
<string-name>
<surname>Young</surname>
<given-names>JW</given-names>
</string-name>, 
<string-name>
<surname>Beitz</surname>
<given-names>DC</given-names>
</string-name>. <article-title>Prevention of fatty liver in transition dairy cows by subcutaneous injections of glucagon</article-title>. <source>J Dairy Sci</source>
<year>2006</year>;<volume>89</volume>:<fpage>1533</fpage>&#x02010;<lpage>1545</lpage>.
<pub-id pub-id-type="pmid">16606724</pub-id></mixed-citation></ref><ref id="hep41171-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="hep41171-cit-0035">
<string-name>
<surname><bold>Liu</bold></surname>
<given-names>Y</given-names>
</string-name>, 
<string-name>
<surname><bold>Fernandez</bold></surname>
<given-names>CA</given-names>
</string-name>, 
<string-name>
<surname>Smith</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Yang</surname>
<given-names>W</given-names>
</string-name>, 
<string-name>
<surname>Cheng</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Panetta</surname>
<given-names>JC</given-names>
</string-name>, et al. <article-title>Genome&#x02010;wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy</article-title>. <source>Clin Pharmacol Ther</source>
<year>2017</year>; doi:<ext-link ext-link-type="doi" xlink:href="10.1002/cpt.629">10.1002/cpt.629</ext-link>.
</mixed-citation></ref><ref id="hep41171-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="hep41171-cit-0036">
<string-name>
<surname>Pillai</surname>
<given-names>SG</given-names>
</string-name>, 
<string-name>
<surname>Duvvuru</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Bhatnagar</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Foster</surname>
<given-names>W</given-names>
</string-name>, 
<string-name>
<surname>Farmen</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Shankar</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro</article-title>. <source>Pharmacogenomics J</source>
<year>2017</year>; doi:<ext-link ext-link-type="doi" xlink:href="10.1038/tpj.2017.45">10.1038/tpj.2017.45</ext-link>.
</mixed-citation></ref><ref id="hep41171-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="hep41171-cit-0037">
<string-name>
<surname>Krawczyk</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Rau</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Schattenberg</surname>
<given-names>JM</given-names>
</string-name>, 
<string-name>
<surname>Bantel</surname>
<given-names>H</given-names>
</string-name>, 
<string-name>
<surname>Pathil</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Demir</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy&#x02010;based study</article-title>. <source>J Lipid Res</source>
<year>2017</year>;<volume>58</volume>:<fpage>247</fpage>&#x02010;<lpage>255</lpage>.
<pub-id pub-id-type="pmid">27836992</pub-id></mixed-citation></ref><ref id="hep41171-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="hep41171-cit-0038">
<string-name>
<surname>Luukkonen</surname>
<given-names>PK</given-names>
</string-name>, 
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, 
<string-name>
<surname>Hyotylainen</surname>
<given-names>T</given-names>
</string-name>, 
<string-name>
<surname>Leivonen</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Arola</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Orho&#x02010;Melander</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non&#x02010;alcoholic fatty liver disease in humans</article-title>. <source>J Hepatol</source>
<year>2016</year>;<volume>65</volume>:<fpage>1263</fpage>&#x02010;<lpage>1265</lpage>.
<pub-id pub-id-type="pmid">27520876</pub-id></mixed-citation></ref><ref id="hep41171-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="hep41171-cit-0039">
<string-name>
<surname><bold>Mancina</bold></surname>
<given-names>RM</given-names>
</string-name>, 
<string-name>
<surname><bold>Dongiovanni</bold></surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Petta</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Pingitore</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Meroni</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Rametta</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>The MBOAT7&#x02010;TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent</article-title>. <source>Gastroenterology</source>
<year>2016</year>;<volume>150</volume>:<fpage>1219</fpage>&#x02010;<lpage>1230</lpage>.e6.
<pub-id pub-id-type="pmid">26850495</pub-id></mixed-citation></ref></ref-list></back></article>